Market closed
Insulet/$PODD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Insulet
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.
Ticker
$PODD
Sector
Trading on
Industry
Health Care Equipment & Supplies
Headquarters
Employees
3,900
Website
Insulet Metrics
BasicAdvanced
$17B
42.61
$5.78
1.29
-
Price and volume
Market cap
$17B
Beta
1.29
52-week high
$289.46
52-week low
$160.19
Average daily volume
834K
Financial strength
Current ratio
3.579
Quick ratio
2.496
Long term debt to equity
111.233
Total debt to equity
118.15
Interest coverage (TTM)
7.23%
Management effectiveness
Return on assets (TTM)
6.80%
Return on equity (TTM)
43.03%
Valuation
Price to earnings (TTM)
42.614
Price to revenue (TTM)
8.338
Price to book
14.28
Price to tangible book (TTM)
16.3
Price to free cash flow (TTM)
58.296
Growth
Revenue change (TTM)
22.07%
Earnings per share change (TTM)
96.55%
3-year revenue growth (CAGR)
23.54%
3-year earnings per share growth (CAGR)
188.85%
What the Analysts think about Insulet
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Insulet stock.
Insulet Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Insulet Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Insulet News
AllArticlesVideos
Insulet to Announce First Quarter 2025 Financial Results on May 8, 2025
Business Wire·3 weeks ago
Insulet's RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod® 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections
Business Wire·1 month ago
Insulet Announces Pricing of Senior Notes Due 2033
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Insulet stock?
Insulet (PODD) has a market cap of $17B as of April 25, 2025.
What is the P/E ratio for Insulet stock?
The price to earnings (P/E) ratio for Insulet (PODD) stock is 42.61 as of April 25, 2025.
Does Insulet stock pay dividends?
No, Insulet (PODD) stock does not pay dividends to its shareholders as of April 25, 2025.
When is the next Insulet dividend payment date?
Insulet (PODD) stock does not pay dividends to its shareholders.
What is the beta indicator for Insulet?
Insulet (PODD) has a beta rating of 1.29. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.